drug pricing reform

Actor Vijay's new party, TVK, has made a significant electoral impact in Tamil Nadu with a welfare-focused manifesto. Promising women's safety, youth employment, and transparent governance through technology, TVK challenges established parties. Key initiatives include monthly aid for women, free LPG, and skill development programs, aiming to reshape the state's political landscape.

An Oxford University expert says obesity is less personal failure than a world built for overeating — and GLP-1 drugs show how biological it is. Can India avoid richer countries’ food mistakes?

NPPA committee faces conflict as industry reps reform pricing rules. Activists criticize the DoP's composition. Will the industry influence drug pricing reforms? Malini Aisola questions industry involvement in policy decisions.

Donald Trump has issued a stern warning to major pharmaceutical companies, demanding they drastically reduce prescription drug prices in the US. In letters to firms like AbbVie, Trump insisted on implementing reforms to lower costs for American patients, who face some of the highest drug prices globally.

Mark Cuban has voiced his support for Donald Trump's healthcare executive order, deeming it a potentially transformative move for the nation. The billionaire believes the drug pricing reforms could yield substantial savings by curbing the influence of pharmacy benefit managers. Cuban advocates for data transparency, independent formulary management, and the protection of independent pharmacies.

President Trump shared a story about a businessman friend's frustration with the high cost of a weight-loss drug in the U.S. compared to Europe, sparking speculation that the friend was Elon Musk, who has publicly admitted using similar medications like Wegovy and Ozempic. Trump's anecdote highlights the broader issue of drug pricing disparities and his administration's efforts to address them.

HYDERABAD: Chief Minister N Chandrababu Naidu on Friday assured the pharmaceutical industry majors that he would pursue with the Central government the issues relating to labour reforms, pricing policy and rationalisation of taxes.

President Trump's "most favored nation" policy aims to drastically lower U.S. prescription drug prices by aligning them with the lowest international rates, impacting global pharmaceutical markets and sparking debate over innovation funding. The initiative, welcomed by many seeking affordable medication, faces challenges from industry influence and concerns about reduced R&D investment. This move represents a significant shift in healthcare policy.

In a demonstration of arbitrary pricing of medicines, pyremethamine, used to treat protozoal infections, went from $13 to $750 a pill in the US, an over 5,000% increase, and down to $1 per pill for a new version, all in a span of just over a month.

The centrepiece of the new policy is the so-called “Most Favoured Nation” (MFN) pricing model, which may sound like a dusty trade clause from a WTO handbook, but is really just code for: If Germany gets a discount, why are we paying full price?

India’s pharma majors Dr Reddy’s and Sun Pharma are among 14 drug makers that are being probed by the US Congress over price escalation of generic drugs.

Reduction in excise duties shows the government is committed to reforms. It also belies expectations that reforms would be put on the backburner because of elections.

Crucial patent law reforms in Philippines may open up a goldmine of opportunity for India's generic pharma industry to export medicines for treating deadly diseases such as HIV and cancer.

Medicines are becoming a major concern in the UAE. Officials are now reviewing how drug prices are set. This review aims to close the gap between official prices and what people actually pay. The government is also looking at boosting local drug manufacturing. These changes are expected to make essential medicines more affordable for everyone in the UAE.

A range of products from instruments to implants to even software intended for medical use in human beings or animals would thus come under the purview of the Drugs and Cosmetics Act, 1940. The move may pave the way for regulation of prices under the Drugs Price Control Order (DPCO). It will also make companies, in case of violations, liable to be penalised in a court of law.

The FDA has drastically cut the time for biosimilar drug approval, aiming to halve the market entry period. This move by the Trump administration targets high biologic drug prices by fostering competition. The reform allows for analytical data to replace extensive human trials, potentially lowering costs for patients and payers while challenging Big Pharma's market dominance.

NEW DELHI: The Union Cabinet is likely to discuss on Tuesday introduction of voluntary retirement scheme in virtually all ministries as recommended by the Expenditure Reforms Commission and consider a proposal on modalities of freeing petroleum sector from price controls.

New Delhi, Aug 18 () The government is mulling fixing trade margins on drugs to bring down costs and create a level-playing field for the pharma industry.

The government plans to cap trade margins to make drugs cheaper, replace brand names with salt names for generic drugs, clamp down on unfair marketing practices and boost local manufacturing to reduce dependence on imports, according to government's draft national pharmaceutical policy.

NEW DELHI: The government is in a hurry. Otherwise, how does one explain the sudden flurry in decision making during the last 20-odd days in February.

Donald Trump announced plans to sign an executive order to slash prescription drug prices in the U.S. by at least 30%, addressing concerns about high medication costs. Trump criticized pharmaceutical companies, claiming Americans bear the brunt of research expenses. He aims to implement a "MOST FAVORED NATION’S" policy, linking U.S.

US President-elect Barack Obama's aggressive agenda on healthcare may prove to be a growth pill for the Indian generic industry.